REVENIO

ENABLING EASY & EFFICIENT DIAGNOSIS

Despite the exceptional circumstances, 2020 ended with very strong net sales and operating profit growth

11.2.2021CEO Jouni ToijalaCFO Robin Pulkkinen



Business Summary of 2020

CEO Jouni Toijala CFO Robin Pulkkinen

REVENIO



Effects of the Covid-19 pandemic

The risks and uncertainties related to the global Covid-19 pandemic grew significantly during the first quarter of 2020. During the second quarter of 2020, a gradual market reopening could already be observed around the world. Towards the end of the year, the uncertainty caused by the Covid-19 pandemic again increased.

The Covid-19 pandemic has not had a significant impact on Revenio's financial position. No material changes have been observed in customers' liquidity.

October – December 2020

MAIN POINTS

19.7 MEUR **NET SALES** +31.7% YoY

8.3 MEUR+43.1%

EBITDA

REVENIO

Positive profit warning for July-December regarding net sales growth was an indication of the organization's excellent ability to adapt quickly to the changed situation

- The strong development of the business was due to the increased demand for iCare intraocular pressure measuring devices and single-use probes, especially in the United States
- Probe production capacity was expanded due to the increased demand
- Successfully conducted remote follow-up audits under the Medical Device Single Audit Program (MDSAP) in both Finland and Italy
- Further development of corporate social responsibility program

January – December 2020

MAIN POINTS


61.1 MEUR **NET SALES** +23.4% YOY

21.7 MEUR +48.4%

EBITDA

REVENIO

- Sales in the United Stated grew strongly during 2020. Demand was particularly strong for iCare intraocular pressure measurement devices and their single-use probes. Sales were also boosted by some unusually large orders
- Sales of intraocular pressure measurement devices (tonometers) and their single-use probes have been good due hygiene issues in the Covid-19 situation
- Imaging devices are capital goods, and their market is expected to recover more slowly, as they require both face-to-face presentations and physical installation and deployment









Key Financials of 2020

Key Figures						
MEUR	1.131.12.2020	1.131.12.2019	Change %	1.1031.12.2020	1.1031.12.2019	Change
Net sales	61,1	49,5	23,4 %	19,7	14,9	31,7
EBIT EBIT %	17,1 28,1 %					46,2 <i>3,8</i>
Adjusted EBIT *** <i>Adjusted EBIT - %</i>	19,1 <i>31,2 %</i>		-			46,2 <i>3,8</i>
Adjusted, EBITDA *** <i>Adjusted, EBITDA - %</i>	21,7 35,5 %	17,4 35,1 %	L			43,1 <i>3,5</i>
Undiluted earnings per share	0,505	0,365		0,222	0,143	
	31.12.2020	31.12.2019	Change %			
Equity ratio-%	60,9 %	58,6 %	2,3 %			
Gearing-%	-2,4 %	3,4 %	-5,8 %			

*** The reference period EBIT & EBITDA have been adjusted by non-recurring acquisition costs and the reporting period EBIT with Q3'2020 Cutica amortizations



Development of key figures



REVENIO

Equity ratio %

Net Gearing %

EBIT % excluding non-recurring items

- Towards the end of the year, the uncertainty caused by the Covid-19 pandemic again increased and the pandemic continues to cause uncertainty related to the markets also in 2021
- Equity ratio has remained strong and net gearing is back to negative after one positive year following the Centervue aquisition
- Operative cashflow over 15 MEUR positive during the year – up 22,8% from 2019



Shareholders and share






Ownership 31.12.2020

#	Owners	Capital	Cou
1	William Demant Invest A/S	10,88 %	Den
2	SEB Funds	4,68 %	Swe
3	Columbia Threadneedle	4,24 %	United
4	Capital Group	2,97 %	United
5	Ilmarinen Mutual Pension Insurance Company	2,50 %	Fin
6	Groupama Asset Management	2,43 %	Fra
7	Aktia Asset Management	1,89 %	Fin
8	Nordea Funds	1,88 %	Fin
9	TIN Funds	1,38 %	Swe
10	Evli Funds	1,32 %	Fin
11	Berenberg Funds	1,23 %	Geri
12	Rauni Siik	1,16 %	Fin
13	Fennia Group	1,15 %	Fin
14	BlackRock	1,02 %	United
15	Dimensional Fund Advisors	0,93 %	United
16	Artisan Partners	0,82 %	United
17	Lannebo Funds	0,78 %	Swe
18	Danske Invest	0,76 %	Swe
19	Longhorn Capital Oy	0,75 %	Fin
20	Mia Alpisalo	0,59 %	Fin

REVENIO

ountry

nmark veden ed States ed States nland rance nland nland veden nland rmany nland nland ed States ed States ed States veden veden nland nland



Share price development



REVENIO

Financial quidance for 2021

Covid-19 pandemic continues to cause uncertainty related to the markets. Revenio Group's exchange rate-adjusted net sales are estimated to grow strongly from the previous year and profitability is to remain at a good level without non-recurring items.

Board's Proposal to the Annual General Meeting

DIVIDEND PROPOSAL EUR 0.32 (0.30)

The Board of Directors will propose to the Annual General Meeting on March 17, 2021 that a pershare dividend of EUR 0.32 (0.30) to be paid.

The remainder of the distributable earnings will be retained in equity.



THANK YOU!

QUESTIONS?

